Introduction
============

Increased low-density lipoprotein-cholesterol (LDL-C) and decreased high-density lipoprotein-cholesterol (HDL-C) are primary risk factors for coronary heart disease (CHD)^[@bib1],\ [@bib2])^. LDL-C is regarded as a primary target for the treatment of dyslipidemia because LDL-C is strongly associated with CHD risk^[@bib3],\ [@bib4])^.

Previous articles reported the association of lipoproteins other than LDL with CHD risk. Very low-density lipoprotein cholesterol (VLDL-C) was shown to be a significant predictor of CHD events in Framingham Heart Study^[@bib5])^. Intermediate-density lipoprotein-cholesterol (IDL-C) was reported to have an association with the severity of CHD^[@bib6])^. Furthermore, IDL-C is significantly increased in type III hyperlipidemia^[@bib7])^. Individuals with chronic kidney disease (CKD) are known to have high levels of triglyceride (TG)-rich lipoproteins including IDL and VLDL^[@bib8])^. Raised IDL-C was associated with aortic sclerosis in hemodialysis patients^[@bib9])^.

We have previously established an analysis method for determining cholesterol concentrations of six lipoprotein classes {HDL, LDL, IDL, VLDL, chylomicron \[CM\] including remnant, and lipoprotein (a) \[Lp (a)\]} by anion-exchange high-performance liquid chromatography (AEX-HPLC) method^[@bib10],\ [@bib11])^. Cholesterol levels of HDL, LDL, IDL, VLDL, and CM measured by AEX-HPLC were sufficiently correlated with those measured by an ultracentrifugation method^[@bib10])^, and Lp (a) cholesterol (Lp (a)-C) measured by AEX-HPLC was correlated with Lp (a) mass using an immunoturbidimetric reagent^[@bib11])^.

Previous studies showed the relationship between lipoprotein cholesterol levels and age. The Framingham study showed changes in mean and percentiles of HDL-C, LDL-C, and VLDL-C by age^[@bib12])^. Arai *et al.* reported changes in total cholesterol (TC), HDL-C, LDL-C, remnant-like particle cholesterol (RLP-C), and TG levels for each 10-year group in general Japanese population^[@bib13])^. Framingham risk score (FRS) was established to estimate the 10-year individual risk of developing CHD in the Framingham Heart Study^[@bib14],\ [@bib15])^. However, the use of the FRS in some populations including the Japanese population resulted in an over-estimation of the CHD risk because the Framingham cohort participants were mainly Caucasian^[@bib16]--[@bib18])^. In Japanese individuals, risk assessment chart was reported for estimating 10-year death probability from CHD-based NIPPON DATA 80 (NIPPON DATA risk), which was a 19-year follow-up study of a Japanese representative population since 1980^[@bib19])^. The Hisayama risk prediction model (Hisayama risk) was established to estimate 10-year risk of cardiovascular disease (CVD) in a general Japanese population based on a cohort study of CVD in the Hisayama town^[@bib20])^. Suita score was established to predict 10-year risk of CHD for Japanese population using the Suita study^[@bib21])^. Suita score includes CKD as a coronary risk factor for Japanese population.

The aims of this study were to estimate the cholesterol levels of six lipoprotein classes in the serum of Japanese healthy men with age and to investigate the relationship between the lipoprotein profiles and three risk scores (NIPPON DATA risk, Hisayama risk, and Suita score) using the data obtained from healthy men.

Materials and Methods
=====================

Subjects
--------

The subjects of this study were the volunteers of the Tokyo Research Center of Tosoh Corporation, which obtained all volunteers\' assents with an informed consent form. The 161 healthy men (age, 25--64 years) without any medications were enrolled in this study. Hypertension was diagnosed based on systolic blood pressure (sBP) \> 140 mmHg and/or diastolic blood pressure (dBP) \> 90 mmHg (according to the Japanese Society of Hypertension Guidelines 2014). The concentration range in sera described the normal state of kidney as estimated glomerular filtration rate (eGFR) \> 60 mL/min/1.73 m^2^ (according to the Japan Society of Nephrology 2013). Dyslipidemia was diagnosed based on TG \> 150 mg/dl, HDL \< 40 mg/dL, and/or LDL \> 140 mg/dL (according to the Japan Atherosclerosis Society Guidelines 2012). A high fasting glucose level was defined as fasting plasma glucose (FPG) \< 110 mg/dl, and/or one of the diagnostic criteria for diabetes was hemoglobin A1c (HbA1c) \< 6.5% (according to the Japan Diabetes Society Guidelines 2013). The normal value ranges of hepatic enzymes \[aspartate transaminase (AST) and alanine transaminase (ALT)\] were \< 30 U/L according to the reference range determined by the Japan Society of Ningen Dock 2012.

Measurement
-----------

The serum AST, ALT, and creatinine (Cre) were measured according to an enzymatic method using Cica Liquid AST, Cica Liquid ALT, and Cica Liquid-S Cre (Kanto Chemical Co, Inc, Tokyo, Japan). The eGFR values were calculated using the new equation proposed by Japanese Society of Nephrology: eGFR for males (mL/min/1.73 m^2^) = 194 × Cr^−1.094^ × Age^−0.287^. TG, TC, HDL-C, and LDL-C levels were measured using Pureauto S TG-N, Choletest CHO, Choletest N HDL, and Choletest LDL (Sekisui Medical, Tokyo, Japan), respectively. FPG and HbA1c were measured using GA08 (A & T Corporation, Kanagawa, Japan) and HLC-723G8 (Tosoh Corporation, Tokyo, Japan), respectively. Non-HDL-C was calculated by subtracting HDL-C from TC. Lp (a)-mass was measured using Lp(a)-LATEX (Denka Seiken, Tokyo, Japan) based on latex-enhanced turbidimetric immunoassay.

Cholesterol levels of HDL, LDL, IDL, and VLDL were measured using HLC-729LPII (Tosoh Corporation) based on AEX-HPLC method^[@bib22])^. Briefly, serum lipoproteins were separated into five lipoprotein classes (HDL, LDL, IDL, VLDL, and other) using a column by elution with step gradient of sodium perchlorate concentration. A column, which contained 2.5 µm of nonporous polymer-based gel with diethylaminoethyl ligands, and 2.5 mm ID × 10 mm in size, and a postcolumn reactor, which contained an enzymatic cholesterol reagent were used. It took 5.2 min to complete the assay of one sample. Cholesterol levels of two lipoprotein classes \[CM and its remnant and Lp (a)\] were measured using AEX-HPLC method described previously^[@bib11])^. Lp (a)-C measured by AEX-HPLC was correlated with Lp (a) mass measured by a latex-enhanced turbidimetric immunoassay (**[Fig. 1](#F1){ref-type="fig"}**). The correlation coefficient was 0.6447 (*P* \< 0.0001, *n* = 161).

![Correlation between Lp (a) mass and Lp (a)-C\
y = 0.0563x + 2.001, *r* = 0.6447, *n* = 161, and *P* \< 0.0001, respectively](jat-24-928-g001){#F1}

10-year CHD death probability (NIPPON DATA risk) was read from NIPPON DATA risk assessment chart using gender, age, sBP, TC, FPG, and smoking tendency^[@bib19])^. 10-year risk score for CVD (Hisayama risk) was calculated by data of gender, age, sBP, smoker, LDL-C, and HDL-C^[@bib20])^. 10-year risk score for CHD (Suita score) was calculated using data of gender, age, LDL-C, HDL-C, blood pressure, diabetes, smoker, and the stage of CKD^[@bib20])^. The stages of CKD were defined by eGFR levels^[@bib21])^.

Statistical Analyses
--------------------

Statistical analyses of the present data were performed by the Stat Flex Ver 6.0 software (Artech Co., Ltd., Osaka, Japan). The data were presented as mean ± standard deviation (SD). The data of multigroups by age were compared with one-way analysis of variance (one-way ANOVA) or Kruskal--Wallis test according to the Bartlett test. All between-groups were compared with two-sample *t*-test or Mann--Whitney test according to the *F*-test. The data of correlations were estimated by Spearman\'s rank test. *P* values \< 0.05 were considered significant. A stepwise multiple logistic regression analysis was performed to determine independent predictors of eGFR.

Results
=======

Healthy study subjects (161 men) were classified into five groups by age (G1: 20--29 years, 28 men; G2: 30--39 years, 55 men; G3: 40--49 years, 39 men; G4: 50--59 years, 31 men; G5: 60--69 years, 8 men). The assay data of classified subjects are summarized in **[Table 1](#T1){ref-type="table"}**. In the data, other than lipid levels, sBP, dBP, ALT, eGFR, FPG, and HbA1c were significantly different among the age groups (one-way ANOVA). In the lipid data, TC, TG, non-HDL-C, and LDL-C measured by direct method were significantly different among the age groups. In lipoprotein data measured by AEX-HPLC, LDL-C, VLDL-C, and CM-C were significantly different among the age groups. In contrast, HDL-C, IDL-C, and Lp(a)-C were not significantly different among the age groups (**[Table 1](#T1){ref-type="table"}**). In the present study, the values of HDL-C, LDL-C, IDL-C, VLDL-C, CM-C, and Lp (a)-C in Japanese healthy men were 62.9 ± 12.7, 101.5 ± 18.1, 8.7 ± 2.5, 18.5 ± 7.5, 0.4 ± 0.9, and 2.6 ± 0.9 mg/dL, respectively. **[Fig. 2](#F2){ref-type="fig"}** showed the lipoprotein profiles between subgroup variations. HDL-C, Lp (a)-C, and Lp (a) mass had no significant difference among the age groups. Significant differences in LDL-C were observed between G1 and G2, G1 and G3, G1 and G4, G1 and G5, and G2 and G3. Significant differences in IDL-C were observed between G1 and G3 and G1 and G4. Significant differences in VLDL-C were observed between G1 and G2, G1 and G3, G1 and G4, and G2 and G4. Significant differences in CM-C were observed between G1 and G2, G1 and G3, G2 and G5, and G3 and G5. NIPPON DATA risk, Hisayama risk, and Suita score were also significantly different with age.

###### Basic data and lipid profiles of six groups by age

                                                                              Total           20\'s           30\'s           40\'s           50\'s           60\'s           *P*
  -------------------------------------------------------- ------------------ --------------- --------------- --------------- --------------- --------------- --------------- -----------
  Age                                                      yeas               40.8 ± 11.0     27.0 ± 1.4      34.1 ± 3.0      44.5 ± 2.8      54.7 ± 2.8      62.8 ± 1.4      \< 0.0001
  BMI                                                      kg/cm^2^           21.9 ± 2.1      21.4 ± 2.4      21.7 ± 2.1      22.4 ± 1.9      22.2 ± 2.1      21.4 ± 2.1      NS
  sBP                                                      mmHg               113.7 ± 10.8    110.4 ± 9.5     110.8 ± 9.7     115.9 ± 11.1    118.3 ± 9.8     115.8 ± 16.1    \< 0.01
  dBP                                                      mmHg               69.6 ± 9.0      65.1 ± 7.7      67.6 ± 7.3      71.2 ± 9.3      75.0 ± 9.5      72.3 ± 9.9      \< 0.0001
  smoker                                                   n, %               31 (19.2%)      4 (14.3%)       11 (20.0%)      6 (15.4%)       9 (29.0%)       1 (12.5%)       
  AST                                                      IU/L               19.6 ± 3.7      18.4 ± 3.8      19.3 ± 3.4      20.1 ± 3.8      20.6 ± 4.4      18.6 ± 2.5      NS
  ALT                                                      IU/L               17.9 ± 4.7      16.6 ± 5.4      18.6 ± 4.3      18.7 ± 4.7      17.6 ± 4.2      14.1 ± 3.7      \< 0.05
  FPG                                                      mg/dL              87.0 ± 6.6      83.5 ± 5.5      85.6 ± 6.0      88.6 ± 5.9      89.2 ± 8.0      91.8 ± 4.6      \< 0.0005
  HbA1c                                                    \%                 5.2 ± 0.3       5.1 ± 0.3       5.1 ± 0.3       5.3 ± 0.3       5.4 ± 0.2       5.5 ± 0.2       \< 0.0001
  Cr                                                       mg/dL              0.836 ± 0.100   0.843 ± 0.094   0.849 ± 0.118   0.827 ± 0.082   0.827 ± 0.090   0.796 ± 0.109   NS
  eGFR                                                     mL/min/1.73 m^2^   83.9 ± 12.7     92.0 ± 11.1     86.6 ± 14.2     81.3 ± 9.3      77.4 ± 10.0     77.2 ± 10.6     \< 0.0001
  Risk Score                                                                                                                                                                  
      Suita score^[\*1](#tf1){ref-type="table-fn"}^        \%                 1.17 ± 0.47                     1.00 ± 0.00     1.00 ± 0.00     1.39 ± 0.67     1.63 ± 0.74     \< 0.0001
      Nippon Data risk^[\*2](#tf2){ref-type="table-fn"}^   \%                 0.60 ± 0.32                                     0.50 ± 0.00     0.53 ± 0.13     1.43 ± 0.54     \< 0.0001
      Hisayama risk^[\*2](#tf2){ref-type="table-fn"}^      \%                 5.13 ± 2.44                                     3.23 ± 0.64     6.61 ± 1.71     9.20 ± 1.99     \< 0.0001
  Lipid Data by usual method                                                                                                                                                  
      HDL-C                                                mg/dL              63.4 ± 12.0     61.4 ± 8.8      63.5 ± 11.7     63.8 ± 12.8     64.0 ± 14.2     63.9 ± 13.2     NS
      LDL-C                                                mg/dL              106.6 ± 20.2    92.6 ± 15.4     104.4 ± 20.3    111.6 ± 20.1    114.8 ± 18.8    117.9 ± 15.4    \< 0.0001
      TC                                                   mg/dL              183.2 ± 24.6    165.6 ± 19.8    180.5 ± 25.7    189.1 ± 24.3    194.0 ± 19.6    196.1 ± 12.3    \< 0.0001
      TG                                                   mg/dL              71.9 ± 26.3     58.2 ± 18.8     68.9 ± 27.2     75.0 ± 21.7     83.4 ± 28.5     81.4 ± 31.9     \< 0.005
      Lp(a)-mass                                           mg/dL              10.9 ± 10.5     9.1 ± 7.7       11.6 ± 9.5      9.3 ± 9.2       12.4 ± 12.8     15.2 ± 22.1     NS
      non-HDL                                              mg/dL              119.8 ± 22.0    104.2 ± 16.4    116.2 ± 21.9    125.4 ± 21.4    130.0 ± 19.6    132.3 ± 18.0    \< 0.0001
  Lipoprotein Data by AEX-HPLC                                                                                                                                                
      HDL-C                                                mg/dL              62.9 ± 12.7     60.6 ± 8.6      63.0 ± 12.7     64.2 ± 14.3     63.0 ± 14.1     61.7 ± 13.4     NS
      LDL-C                                                mg/dL              101.5 ± 18.1    88.8 ± 13.2     99.5 ± 18.6     107.5 ± 18.8    107.6 ± 14.9    111.2 ± 12.9    \< 0.0001
      IDL-C                                                mg/dL              8.7 ± 2.5       7.7 ± 2.6       8.8 ± 2.7       9.2 ± 2.2       9.2 ± 1.9       8.2 ± 2.3       NS
      VLDL-C                                               mg/dL              18.5 ± 7.5      14.1 ± 4.7      18.1 ± 7.7      20.1 ± 7.4      21.6 ± 7.9      18.3 ± 7.3      \< 0.005
      CM-C                                                 mg/dL              0.4 ± 0.9       0.3 ± 0.2       0.2 ± 0.2       0.4 ± 1.2       0.5 ± 1.3       0.4 ± 0.2       \< 0.01
      Lp (a)-C                                             mg/dL              2.6 ± 0.9       2.6 ± 0.9       2.7 ± 1.3       2.6 ± 0.9       2.6 ± 1.0       3.0 ± 1.4       NS
      TC                                                   mg/dL              194.7 ± 25.9    174.1 ± 18.3    192.3 ± 28.1    204.0 ± 24.9    204.5 ± 19.8    202.8 ± 12.9    \< 0.0001

Values are presented as mean ± SD.

Statical significance was assessed using Kruskal-Wallis test or one way ANOVA.

BMI, body mass index; sBP, systolic blood pressures; dBP, diastolic blood pressures; AST, Aspartate transaminase; ALT, Alanine transaminase; FPG, fasting plasma glucose; HbA1c, hemogrobin A1c; Cr, creatinine; eGFR, estimated glomerularfiltration rate.

Suita score was caluculated, excluded under 34 year age subjects.

NIPPON DATA risk and Hisayama risk were calculated using excluded under 39 year age subjects.

![Comparison of the cholesterol concentration of six lipoproteins as per age using AEX-HPLC\
The cholesterol levels of HDL, LDL, IDL, VLDL, CM, and Lp (a) were compared by age groups.\
The values indicate the mean ± standard deviation and they were shown in [Table 1](#T1){ref-type="table"}.\
All between-groups were compared using two-sample *t*-test or Mann-Whitney test according to *F*-test.\
\*: *p* \< 0.05, \*\*: *p* \< 0.01, \*\*\*: *p* \< 0.001](jat-24-928-g002){#F2}

The correlations between the cholesterol levels of each lipoprotein measured by AEX-HPLC and the other clinical parameters are shown in **[Table 2](#T2){ref-type="table"}**. HDL-C was inversely related to body mass index (BMI). LDL-C was positively correlated with BMI, sBP, dBP, FPG, and Suita score and inversely correlated with eGFR. IDL-C was positively correlated with BMI and inversely correlated with eGFR. VLDL-C was positively correlated with BMI, sBP, and dBP and inversely correlated with eGFR. CM-C was positively correlated with BMI, sBP, NIPPON DATA risk, Hisayama risk, and Suita score. However, Lp (a)-C and Lp (a) mass did not correlate with any other clinical parameters. Non-HDL-C was positively correlated with BMI, sBP, dBP, FPG, and Suita score and inversely correlated with eGFR.

###### Correlation coefficients between lipoprotein data by AEX-HPLC and clinical characteristics

                                             Age         BMI         sBP         dBP      AST      ALT       FPG     HbA1c      Cr          eGFR       Suita score^[\*1](#tf3){ref-type="table-fn"}^   NIPPON DATA risk^[\*2](#tf4){ref-type="table-fn"}^   Hisayama risk^[\*2](#tf4){ref-type="table-fn"}^
  ------------------------------ ----------- ----------- ----------- ----------- -------- -------- --------- ------- ---------- ----------- ---------- ----------------------------------------------- ---------------------------------------------------- -------------------------------------------------
  Number                                     161         103         77          77                                                                                                                                                                         
                                                                                                                                                                                                                                                            
  Lp(a)-mass                     rS          −0.008      −0.018      0.073       0.067    0.105    0.098     0.054   −0.057     0.066       −0.058     0.099                                           −0.042                                               0.171
  *P* values                     NS          NS          NS          NS          NS       NS       NS        NS      NS         NS          NS         NS                                              NS                                                   
  non-HDL                        rS          0.407       0.346       0.34        0.319    0.038    0.137     0.218   0.103      0.166       −0.330     0.292                                           0.049                                                0.073
  *P* values                     \< 0.0001   \< 0.0001   \< 0.0001   \< 0.0001   NS       NS       \< 0.01   NS      \< 0.05    \< 0.0001   \< 0.005   NS                                              NS                                                   
  Lipoprotein data by AEX-HPLC                                                                                                                                                                                                                              
      HDL-C                      rS          0.056       −0.253      −0.083      −0.020   0.151    −0.013    0.110   0.043      −0.154      0.111      −0.043                                          −0.065                                               −0.057
  *P* values                     NS          \< 0.005    NS          NS          NS       NS       NS        NS      NS         NS          NS         NS                                              NS                                                   
      LDL-C                      rS          0.364       0.302       0.308       0.286    0.044    0.087     0.187   0.108      0.088       −0.238     0.202                                           0.007                                                −0.044
  *P* values                     \< 0.0001   \< 0.0001   \< 0.0001   \< 0.0005   NS       NS       \< 0.05   NS      NS         \< 0.005    \< 0.05    NS                                              NS                                                   
      IDL-C                      rS          0.213       0.193       0.102       0.064    −0.080   0.046     0.096   0.059      0.178       −0.258     −0.176                                          −0.123                                               −0.151
  *P* values                     \< 0.01     \< 0.05     NS          NS          NS       NS       NS        NS      \< 0.05    \< 0.001    NS         NS                                              NS                                                   
      VLDL-C                     rS          0.294       0.239       0.203       0.170    −0.120   0.121     0.033   0.108      0.265       −0.349     0.013                                           −0.136                                               −0.078
  *P* values                     \< 0.005    \< 0.005    \< 0.01     \< 0.05     NS       NS       NS        NS      \< 0.001   \< 0.0001   NS         NS                                              NS                                                   
      CM-C                       rS          0.083       0.186       0.180       0.119    0.017    0.081     0.093   0.030      0.134       −0.160     0.290                                           0.242                                                0.279
  *P* values                     NS          \< 0.05     \< 0.05     NS          NS       NS       NS        NS      NS         \< 0.05     \< 0.005   \< 0.005                                        \< 0.005                                             
      Lp(a)-C                    rS          −0.009      −0.001      0.121       0.080    0.220    0.154     0.095   −0.013     0.050       −0.055     0.016                                           0.041                                                0.036
  *P* values                     NS          NS          NS          NS          NS       NS       NS        NS      NS         NS          NS         NS                                              NS                                                   

Not significant is indicaied by NS.

Statical significance was assessed using Speaman\'s rank correlation coefficient (rS).

BMI, body mass index; sBP, systolic blood pressures; dBP, diastolic blood pressures; AST, Aspartate transaminase; ALT, Alanine transaminase; FPG, fasting plasma glucose; HbA1c, hemogrobin A1c; Cr, creatinine; eGFR, estimated glomerularfiltration rate.

Suita score was caluculated using excluded under 34 year age subjects.

NIPPON DATA risk and Hisayama risk were calculated using excluded under 39 year age subjects.

Next, we compared the cholesterol levels of each lipoprotein measured by AEX-HPLC and the other clinical parameters in subgroups classified based on Suita score (**[Table 3](#T3){ref-type="table"}**). Age, sBP, dBP, and HbA1c were significantly different by Suita score. LDL-C, TC, and non-HDL-C by usual method were significantly different by Suita score. In lipoprotein data measured by AEX-HPLC, the significant difference by Suita score was found only in CM-C.

###### Basic data and lipid profiles of each Suita score groups

  Suita score                    0%                 1%              2%              3%              *P*             
  ------------------------------ ------------------ --------------- --------------- --------------- --------------- -----------
  Age                            yeas               43.0 ± 5.7      54.8 ± 6.1      59.1 ± 3.7      58.0 ± 3.6      \< 0.0001
  BMI                            kg/cm^2^           22.1 ± 1.9      22.4 ± 2.7      21.9 ± 1.5      22.0 ± 2.7      NS
  sBP                            mmHg               113.2 ± 10.0    117.7 ± 12.6    124.0 ± 7.4     132.5 ± 2.5     \< 0.0005
  dBP                            mmHg               69.0 ± 8.1      74.1 ± 10.5     81.6 ± 7.0      80.5 ± 7.7      \< 0.0001
  smoker                         n, %               16 (23%)        4 (21%)         2 (22%)         3 (75%)         NS
  AST                            IU/L               19.5 ± 3.6      20.4 ± 4.4      21.2 ± 3.8      20.3 ± 1.0      NS
  ALT                            IU/L               18.9 ± 4.6      17.1 ± 5.2      17.7 ± 3.2      13.5 ± 2.4      NS
  FPG                            mg/dL              87.6 ± 6.3      91.8 ± 6.9      89.4 ± 6.2      91.8 ± 5.5      \< 0.05
  HbA1c                          \%                 5.2 ± 0.3       5.4 ± 0.2       5.3 ± 0.1       5.3 ± 0.3       NS
  Cr                             mg/dL              0.840 ± 0.093   0.831 ± 0.101   0.827 ± 0.102   0.822 ± 0.100   NS
  eGFR                           mL/min/1.73 m^2^   81.1 ± 10.3     76.7 ± 10.7     75.2 ± 10.1     75.8 ± 9.4      
  Lipid Data by usual method                                                                                        
      HDL-C                      mg/dL              63.2 ± 11.5     64.8 ± 14.0     66.9 ± 16.1     58.8 ± 10.3     NS
      LDL-C                      mg/dL              108.0 ± 19.3    119.7 ± 14.8    117.8 ± 13.7    127.5 ± 13.5    \< 0.05
      TC                         mg/dL              184.9 ± 23.3    198.8 ± 12.6    199.0 ± 17.3    202.5 ± 6.8     \< 0.05
      TG                         mg/dL              75.2 ± 25.3     80.2 ± 21.5     84.9 ± 35.1     93.3 ± 45.6     NS
      Lp(a)-mass                 mg/dL              9.9 ± 8.9       13.4 ± 15.2     15.9 ± 19.4     9.0 ± 5.6       NS
      non-HDL-C                  mg/dL              121.7 ± 20.9    134.0 ± 15.3    132.1 ± 16.2    143.8 ± 14.5    \< 0.05
  Lipoprotein Data by AEX-HPLC                                                                                      
      HDL-C                      mg/dL              63.3 ± 12.8     63.3 ± 14.5     64.4 ± 14.4     55.9 ± 10.9     NS
      LDL-C                      mg/dL              103.7 ± 18.1    111.1 ± 13.4    110.6 ± 12.4    118.6 ± 9.2     NS
      IDL-C                      mg/dL              9.4 ± 2.1       8.6 ± 2.1       8.5 ± 2.2       8.8 ± 0.8       NS
      VLDL-C                     mg/dL              20.1 ± 7.4      20.4 ± 8.1      20.5 ± 9.4      21.2 ± 9.3      NS
      CM-C                       mg/dL              0.3 ± 0.9       0.7 ± 1.7       0.3 ± 0.1       0.5 ± 0.3       \< 0.05
      Lp (a)-C                   mg/dL              2.6 ± 0.9       2.5 ± 1.0       2.9 ± 1.4       3.1 ± 0.8       NS
      TC                         mg/dL              199.5 ± 24.4    206.6 ± 15.6    207.1 ± 18.9    208.0 ± 9.3     \< 0.05

Values are presented as mean ± SD.

Statical significance was assessed using Kruskal-Wallis test or one way ANOVA.

BMI, body mass index; sBP, systolic blood pressures; dBP, diastolic blood pressures; AST, Aspartate transaminase; ALT, Alanine transaminase; FPG, fasting plasma glucose; HbA1c, hemogrobin A1c; Cr, creatinine; eGFR, estimated glomerularfiltration rate.

Suita score was calculated, excluded under 34 year age subjects.

Then, the study subjects (161 men) were classified into tertile groups based on eGFR levels \[T1 (Low tertile; eGFR 60.2--76.3 mL/min/1.73 m^2^), T2 (Middle tertile; eGFR 76.6--88.4 mL/min/1.73 m^2^), and T3 (High tertile; eGFR 88.7--117.1 mL/min/1.73 m^2^)\]. Although our present study used the healthy subjects without CKD, Suita score was calculated with eGFR, which was the biomarker of CKD^[@bib21])^. The data of classified subjects are shown in **[Table 4](#T4){ref-type="table"}**. In the data other than lipid levels, age, BMI, and sBP were significantly different among the eGFR groups. In lipid data, LDL-C, TC, TG, and non-HDL-C were significantly different among the eGFR groups. In lipoprotein data measured by AEX-HPLC, LDL-C, IDL-C, and VLDL-C were significantly different among the eGFR groups.

###### Basic data and lipid profiles of tertile groups by eGFR

  eGFR range (mL/min/1.73 m^2^)                        T1 (Low tertile)      T2 (Middle tertile)   T3 (High tertile)     *P*             
  ---------------------------------------------------- --------------------- --------------------- --------------------- --------------- -----------
  Number (35 over^[\*1](#tf6){ref-type="table-fn"}^)   *n* = 53 (*n* = 42)   *n* = 54 (*n* = 44)   *n* = 54 (*n* = 17)                   
  Age                                                  yeas                  45.3 ± 10.5           42.8 ± 10.2           34.3 ± 9.1      \< 0.0001
  BMI                                                  kg/cm^2^              22.4 ± 1.8            22.0 ± 2.1            21.3 ± 2.3      \< 0.05
  sBP                                                  mmHg                  115.6 ± 10.9          114.8 ± 10.4          110.8 ± 10.6    \< 0.05
  dBP                                                  mmHg                  70.3 ± 9.2            70.7 ± 8.6            67.9 ± 9.1      NS
  smoker                                               n, %                  12 (22.6%)            10 (18.5%)            9 (16.7%)       
  AST                                                  IU/L                  20.51 ± 3.79          19.0 ± 3.8            19.2 ± 3.5      NS
  ALT                                                  IU/L                  18.55 ± 4.66          17.9 ± 4.5            17.1 ± 4.9      NS
  FPG                                                  mg/dL                 88.0 ± 7.03           87.7 ± 6.4            85.2 ± 6.3      NS
  HbA1c                                                \%                    5.3 ± 0.4             5.2 ± 0.3             5.2 ± 0.2       NS
  Cr                                                   mg/dL                 0.935 ± 0.065         0.829 ± 0.060         0.745 ± 0.062   \< 0.0001
  eGFR                                                 mL/min/1.73 m^2^      70.7 ± 3.9            82.0 ± 3.2            98.5 ± 7.9      \< 0.0001
  Suita score^[\*1](#tf6){ref-type="table-fn"}^        \%                    0.41 ± 0.87           0.59 ± 0.87           0.38 ± 0.73     NS
  Lipid Data by usual method                                                                                                             
      HDL-C                                            mg/dL                 62.0 ± 12.8           66.1 ± 10.8           62.1 ± 12.0     NS
      LDL-C                                            mg/dL                 111.0 ± 18.3          110.2 ± 19.0          98.5 ± 21.1     \< 0.005
      TC                                               mg/dL                 188.2 ± 20.9          188.8 ± 23.5          172.7 ± 26.1    \< 0.0005
      TG                                               mg/dL                 81.1 ± 27.7           74.0 ± 24.7           60.7 ± 22.4     \< 0.0005
      Lp(a)-mass                                       mg/dL                 11.8 ± 11.0           10.1 ± 8.7            10.7 ± 11.6     NS
      non-HDL-C                                        mg/dL                 126.2 ± 20.1          122.7 ± 20.3          110.6 ± 22.7    \< 0.0005
  Lipoprotein Data by AEX-HPLC                                                                                                           
      HDL-C                                            mg/dL                 60.9 ± 13.7           65.0 ± 10.8           62.7 ± 13.4     NS
      LDL-C                                            mg/dL                 105.0 ± 16.4          104.3 ± 18.4          95.4 ± 18.0     \< 0.01
      IDL-C                                            mg/dL                 9.4 ± 2.3             9.1 ± 2.3             7.8 ± 2.5       \< 0.005
      VLDL-C                                           mg/dL                 21.5 ± 8.0            19.0 ± 6.9            15.2 ± 6.3      \< 0.0001
      CM-C                                             mg/dL                 0.4 ± 1.1             0.3 ± 0.2             0.4 ± 1.0       NS
      Lp (a)-C                                         mg/dL                 2.7 ± 0.9             2.4 ± 0.7             2.7 ± 1.1       NS
      TC                                               mg/dL                 199.9 ± 22.2          200.0 ± 24.5          184.2 ± 27.9    \< 0.005

Values are presented as mean ± SD.

Statical significance was assessed using Kruskal-Wallis test or one way ANOVA.

BMI, body mass index; sBP, systolic blood pressures; dBP, diastolic blood pressures; AST, Aspartate transaminase; ALT, Alanine transaminase; FPG, fasting plasma glucose; HbA1c, hemogrobin A1c; Cr, creatinine; eGFR, estimated glomerularfiltration rate.

Suita score was caluculated, excluded under 34 year age subjects.

Finally, the TG-rich lipoproteins and Lp (a)-C that contribute to eGFR were of interest. In a multiple regression analysis, we used BMI as a confounding factor correlated to the reduced eGFR (*P* = 0.0042). A multiple regression analysis indicated that VLDL-C value was significantly correlated with a reduced eGFR independent of BMI (**[Table 5](#T5){ref-type="table"}**).

###### A stepwise multiple regression analysis of the eGFR and various parameters (*n* = 161)

                                            Standard regression coefficients (*β*)   *t* value   *P* value
  ----------------------------------------- ---------------------------------------- ----------- -----------
  Basic data                                                                                     
      Body mass index (kg/m^2^)             −0.7046                                  1.55254     0.1225
  Lipoprotein data by anion-exchange HPLC                                                        
      HDL-C (mg/dL)                         Not remain                                           
      LDL-C (mg/dL)                         −0.1106                                  1.96497     0.0512
      IDL-C (mg/dL)                         Not remain                                           
      VLDL-C (mg/dL)                        0.4738                                   3.56106     \< 0.0005
      CM-C (mg/dL)                          Not remain                                           
      Lp(a)-C (mg/dL)                       Not remain                                           

Discussion
==========

Previous studies have reported the relation of HDL-C, LDL-C, VLDL-C, or TC levels to age. A study reported by Arai *et al.* showed the age-specific means and SDs of serum TC, HDL-C, LDL-C, TG, and RLP-C levels by age group in the general Japanese population, and HDL-C and LDL-C were measured by homogeneous assays^[@bib13])^. Abbott *et al.* reported the cholesterol content of lipoprotein density classes measured by ultracentrifugation in the Framingham study during the period from 1971 to 1975 and the variations of HDL-C, LDL-C, and VLDL-C by age, gender, and use of hormone preparations^[@bib12])^. **[Fig. 3](#F3){ref-type="fig"}** shows the comparison levels of HDL-C, LDL-C, and VLDL-C by age group between the results of this study, the Japanese data reported by Arai *et al.*^[@bib13])^, and the Framingham study data^[@bib12])^. Because LDL-C in the Japanese data by Arai *et al.* and the Framingham study data included IDL-C, we used the sum of LDL-C and IDL-C measured by AEX-HPLC as LDL-C for comparison^[@bib11],\ [@bib22])^. Compared with the Japanese data by Arai *et al.*, given that the subjects in the survey data represented the civilian Japanese population having dyslipidemia, similar trends are observed in HDL-C and LDL-C. The concentration of HDL-C is lower in the Framingham study than in this study data measured by AEX-HPLC although similar trends are observed in HDL-C, LDL-C, and VLDL-C, while the concentration of LDL-C and VLDL-C was higher in the Framingham study than in this study data presumably because the subjects with hyperlipidemia were included in the Framingham study. The present study results need to be validated using large-scale study in the future.

![Mean concentration of cholesterol in HDL, LDL (LDL + IDL), and VLDL in relation to age\
Square indicates mean concentration of cholesterol measured by AEX-HPLC.\
Circle indicates mean concentration of Japanese lipid survey reported by Arai *et al.* in 2005^[@bib13])^.\
Triangle indicates mean concentration of the Framingham study reported by Abbott *et al.* in 1982^[@bib12])^.\
Because LDL-C in these study data included IDL-C, we used the sum of LDL-C and IDL-C measured by AEX-HPLC as LDL-C for comparison.](jat-24-928-g003){#F3}

In this study, Lp (a)-C levels did not show the significant variations by age group. Lp(a)-C levels seem to be little affected by age in healthy subjects because Lp (a) levels are profoundly affected by genetic factor^[@bib23])^. We used the Lp(a)-LATEX (Denka Seiken, Tokyo, Japan) to measure Lp (a) mass, which was reported to be in harmony with the reference method and exhibited a positive bias for samples with apolipoprotein (a) {apo (a)} isoforms containing \> 25 kringle 4 domains^[@bib24])^. In this study group, Lp (a)-C values were distributed within a relatively narrow and low range (2.6 ± 0.9 mg/dL). Lp (a)-C measured by AEX-HPLC was well correlated with Lp (a) mass (**[Fig. 1](#F1){ref-type="fig"}**). Several methods to measure Lp (a)-C were previously reported. Nauck *et al.* reported direct determination of Lp (a)-C by ultracentrifugation and agarose gel electrophoresis^[@bib25])^. Sheman *et al.* reported a measurement method with lectin affinity to isolate Lp (a) from other lipoproteins^[@bib26])^. The comparison between these methods and our AEX-HPLC should be performed in the future. Some studies have suggested that high Lp (a) levels and the presence of smallermolecular size of apo (a) are risk factors for atherosclerotic disease^[@bib26]--[@bib28])^. The values of Lp (a)-C in healthy subjects showed little difference by age and no significant correlations with the clinical parameters associated with diabetes, CKD, or CHD (**[Table 2](#T2){ref-type="table"}**). These Lp (a)-C results of subjects with dyslipidemia remain to be defined.

It has been reported that individuals with CKD have increased levels of TG-rich lipoproteins^[@bib8])^. The CKD stage is defined using eGFR levels by the K/DOQI clinical practice guidelines^[@bib8])^. In this study, LDL-C, IDL-C, VLDL-C, and CM-C measured by AEX-HPLC were inversely correlated with eGFR (**[Table 2](#T2){ref-type="table"}**). LDL-C, IDL-C, and VLDL-C measured by AEX-HPLC were significantly different among eGFR tertile groups (**[Table 4](#T4){ref-type="table"}**). The multiple regression analysis showed that VLDL-C level was a significant explanatory factor for eGFR (**[Table 5](#T5){ref-type="table"}**). Shoji *et al.* showed that IDL-C and VLDL-C in hemodialysis patients were higher in patients with CKD than in healthy control^[@bib9])^. The VLDL receptor binds VLDL and participates in the clearance of VLDL from the circulation^[@bib29])^.

Previous study reported that VLDL receptor mRNA and protein are reduced in chronic renal failure rat models subjected to surgical partial nephrectomy or parathyroidectomy^[@bib30])^.

Moreover, hepatic lipase gene expression is depressed in rats with experimental chronic renal failure (CRF), and lipoprotein lipase expression is downregulated by CRF rats^[@bib31],\ [@bib32])^. The downregulation of VLDL receptor pathway leads to an increase in plasma concentration and depressing clearance of VLDL in the early stage of CKD^[@bib33])^. Moreover, earlier atherosclerosis in kidneys is considered to induce intrarenal microvascular disease and renal injury in patients with CKD^[@bib34])^. Previous reports showed that IDL and VLDL were associated with atherosclerosis progression^[@bib35],\ [@bib36])^. Thus, VLDL-C might be a good marker to predict renal dysfunction in healthy subjects. We need some case studies of patients with hypertension, diabetes mellitus, and dyslipidemia in addition to the present study to clarify that VLDL-C was also associated with eGFR in each diseased group.

Suita score was established to estimate the 10-year risk of CHD for Japanese population, and CKD is used for Suita score as a coronary risk factor^[@bib21])^. Suita score is much lower than FRS for the 10-year prediction of CHD events, which suggests that Suita score may be better than FRS to evaluate CHD risk for healthy Japanese population^[@bib21])^. In Spearman\'s rank test data, Suita core score was significantly correlated with age (*P* \< 0.0001), sBP (*P* \< 0.0001), dBP (*P* \< 0.0001), FPG(*P* \< 0.01), HbA1c (\< 0.05), eGFR (\< 0.05), and LDL-C (\< 0.05), but not with HDL-C. CM-C was observed significant difference with Suita score (*P* = 0.003) as well as NIPPON DATA risk and Hisayama risk (**[Table 2](#T2){ref-type="table"}**). Furthermore, CM-C was significantly different in subgroups classified by Suita score (**[Table 3](#T3){ref-type="table"}**). Because LDL-C measured by homogeneous assay included IDL-C, LDL-C by AEX-HPLC might be not be significantly different unlike LDL-C by homogeneous assay. It was known that CM remnant was a predictor of atherosclerotic risk^[@bib37]--[@bib39])^ and CM remnant is relatively enriched in cholesterol ester^[@bib40])^. In this study, the cholesterol level in CM measured by AEX-HPLC mainly showed CM remnant cholesterol. It was considered that the remnant particles including CM remnant can enter the arterial wall and might increase the risk of atherogenesis^[@bib41],\ [@bib42])^ LDL receptor-related proteins (LRPs) are a member of LDL receptor gene family and recognized some ligands including IDL and CM remnant^[@bib31],\ [@bib43])^. Fujioka *et al.* suggested that CM remnants are taken up by via LDL receptor and LRP^[@bib44])^. Elevated CM remnant cholesterol might represent the functional depression of LRP. Our data indicated that the CM-C by AEX-HPLC may be an independent marker for estimating CHD risk in healthy men. Nishimura *et al.* reported that the FRS overestimated the risk of CHD in Japanese subjects, especially in the non-CHD group, and the risks of hypertension and low HDL-C for males in the Suita cohort were weighted higher than the risk in the Framingham cohort^[@bib21])^. For these reasons, IDL-C or VLDL-C might not be significantly correlated with Suita score in the present healthy subjects. Non-HDL-C is composed of LDL-C, IDL-C, VLDL-C, and CM-C^[@bib45])^. We indicated the good correlation between Suita score and non-HDL-C in **[Table 2](#T2){ref-type="table"}** and thought that the correlation was attributed to the associations between Suita score and LDL-C and CM-C. The present study has two limitations. One is that in the CM-C levels in Suita score, 1% subgroup was widely present (0.7 ± 1.7 mg/dL). Another was that in the present study, there was lack of subjects with CKD, and Suita score was characterized by CKD^[@bib21])^. Then, we also analyzed using other risk scores in the Japanese population in addition to Suita score. NIPPON DATA risk was the risk assessment chart for estimating score of 10-year death probability from CHD-based NIPPON DATA 80^[@bib19])^. The Hisayama risk was established to estimate 10-year risk of CVD-based Hisayama study^[@bib20])^. NIPPON DATA risk and Hisayama risk were similar to Suita score and significantly different among the age groups. Moreover, significant difference was also observed with CM-C. In contrast, significant difference was not observed with non-HDL-C. To reconfirm the relationship between CM-C and Suita score or non-HDL-C and risk factors more clearly, we need a further large-scale study including some diseased subjects.

In conclusion, LDL-C, VLDL-C, and CM-C were significantly different as per age, and HDL-C, IDL-C, and Lp(a)-C were not significantly different in Japanese healthy men. VLDL-C value significantly correlated with eGFR. CM-C significantly correlated with Suita score. These results suggests that the increased serum VLDL-C concentration may contribute to an increased risk at early stages of renal dysfunction and that CM-C may serve as a useful marker for estimating CHD risk in Japanese healthy men although further studies are still needed.
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